AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023


AbbVie Inc on Thursday said it signed a deal with Biogen Inc and its joint venture partner Samsung Bioepis that would fend off U.S. competition of their rival version to blockbuster drug Humira until 2023. This is the second deal AbbVie has signed over the past year as it tries to safeguard patents on Humira, which is the world's top-selling prescription medicine.



from Biotech News